The Current Status and Future Prospects of Oncolytic Viruses in Clinical Trials against Melanoma, Glioma, Pancreatic, and Breast Cancers

Oncolytic viral therapy has been accepted as a standard immunotherapy since talimogene laherparepvec (T-VEC, Imlygic(®)) was approved by the Food and Drug Administration (FDA) and European Medicines Agency (EMA) for melanoma treatment in 2015. Various oncolytic viruses (OVs), such as HF10 (Canerpatu...

Descripción completa

Detalles Bibliográficos
Autores principales: Eissa, Ibrahim Ragab, Bustos-Villalobos, Itzel, Ichinose, Toru, Matsumura, Shigeru, Naoe, Yoshinori, Miyajima, Noriyuki, Morimoto, Daishi, Mukoyama, Nobuaki, Zhiwen, Wu, Tanaka, Maki, Hasegawa, Hitoki, Sumigama, Seiji, Aleksic, Branko, Kodera, Yasuhiro, Kasuya, Hideki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6210336/
https://www.ncbi.nlm.nih.gov/pubmed/30261620
http://dx.doi.org/10.3390/cancers10100356

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6210336/
https://www.ncbi.nlm.nih.gov/pubmed/30261620
http://dx.doi.org/10.3390/cancers10100356

Ejemplares similares